165 related articles for article (PubMed ID: 20393015)
1. Establishment and characterization of multidrug-resistant gastric cancer cell lines.
Zhang X; Yashiro M; Qiu H; Nishii T; Matsuzaki T; Hirakawa K
Anticancer Res; 2010 Mar; 30(3):915-21. PubMed ID: 20393015
[TBL] [Abstract][Full Text] [Related]
2. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
Qiu H; Yashiro M; Zhang X; Miwa A; Hirakawa K
Cancer Lett; 2011 Aug; 307(1):47-52. PubMed ID: 21482024
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Zhang X; Yashiro M; Ren J; Hirakawa K
Oncol Rep; 2006 Sep; 16(3):563-8. PubMed ID: 16865256
[TBL] [Abstract][Full Text] [Related]
4. Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines.
Liu Z; Qiu M; Tang QL; Liu M; Lang N; Bi F
Chin J Cancer; 2010 Jul; 29(7):661-7. PubMed ID: 20591218
[TBL] [Abstract][Full Text] [Related]
5. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.
Zhao Q; Zhang H; Li Y; Liu J; Hu X; Fan L
J Exp Clin Cancer Res; 2010 Aug; 29(1):118. PubMed ID: 20799994
[TBL] [Abstract][Full Text] [Related]
7. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
Yashiro M; Qiu H; Hasegawa T; Zhang X; Matsuzaki T; Hirakawa K
Br J Cancer; 2011 Nov; 105(10):1522-32. PubMed ID: 21997136
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
9. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma.
Yashiro M; Nishii T; Hasegawa T; Matsuzaki T; Morisaki T; Fukuoka T; Hirakawa K
Br J Cancer; 2013 Nov; 109(10):2619-28. PubMed ID: 24129235
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Wattanawongdon W; Hahnvajanawong C; Namwat N; Kanchanawat S; Boonmars T; Jearanaikoon P; Leelayuwat C; Techasen A; Seubwai W
Int J Oncol; 2015 Jul; 47(1):398-410. PubMed ID: 25998688
[TBL] [Abstract][Full Text] [Related]
11. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
[TBL] [Abstract][Full Text] [Related]
12. Protection of stromal cell-derived factor 2 by heat shock protein 72 prevents oxaliplatin-induced cell death in oxaliplatin-resistant human gastric cancer cells.
Takahashi K; Tanaka M; Yashiro M; Matsumoto M; Ohtsuka A; Nakayama KI; Izumi Y; Nagayama K; Miura K; Iwao H; Shiota M
Cancer Lett; 2016 Aug; 378(1):8-15. PubMed ID: 27157913
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
[TBL] [Abstract][Full Text] [Related]
14. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
Ganten TM; Koschny R; Sykora J; Schulze-Bergkamen H; Büchler P; Haas TL; Schader MB; Untergasser A; Stremmel W; Walczak H
Clin Cancer Res; 2006 Apr; 12(8):2640-6. PubMed ID: 16638878
[TBL] [Abstract][Full Text] [Related]
15. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Oguri T; Achiwa H; Bessho Y; Muramatsu H; Maeda H; Niimi T; Sato S; Ueda R
Lung Cancer; 2005 Sep; 49(3):345-51. PubMed ID: 15993511
[TBL] [Abstract][Full Text] [Related]
16. Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library.
Zhao L; Pan Y; Gang Y; Wang H; Jin H; Tie J; Xia L; Zhang Y; He L; Yao L; Qiao T; Li T; Liu Z; Fan D
J Biol Chem; 2009 Sep; 284(39):26273-85. PubMed ID: 19638344
[TBL] [Abstract][Full Text] [Related]
17. The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol.
Li L; Jiang AC; Dong P; Wan Y; Yu ZW
Otolaryngol Head Neck Surg; 2007 Oct; 137(4):659-64. PubMed ID: 17903587
[TBL] [Abstract][Full Text] [Related]
18. Effect of betulinic acid on anticancer drug-resistant colon cancer cells.
Jung GR; Kim KJ; Choi CH; Lee TB; Han SI; Han HK; Lim SC
Basic Clin Pharmacol Toxicol; 2007 Oct; 101(4):277-85. PubMed ID: 17845510
[TBL] [Abstract][Full Text] [Related]
19. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia.
Mohamed F; Marchettini P; Stuart OA; Urano M; Sugarbaker PH
Ann Surg Oncol; 2003 May; 10(4):463-8. PubMed ID: 12734097
[TBL] [Abstract][Full Text] [Related]
20. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
